These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33693494)

  • 1. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study.
    Lin Y; Chen X; Ding H; Ye P; Gu J; Wang X; Jiang Z; Li D; Wang Z; Long W; Li Z; Jiang G; Li X; Bi L; Jiang L; Wu J; Guo L; Cai X; Lu X; Chen Q; Chen H; Peng A; Zuo X; Ning R; Zhang Z; Tai Y; Zhang T; Bao C
    Rheumatology (Oxford); 2021 Nov; 60(11):5089-5097. PubMed ID: 33693494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study.
    Tang H; Cui B; Chen Y; Chen L; Wang Z; Zhang N; Yang Y; Wang X; Xie X; Sun L; Dang W; Wang X; Li R; Zou J; Zhao Y; Liu Y
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X211067304. PubMed ID: 35126684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
    Dua P; Gurrell R; Kirby S; Sudworth M; Loudon PT
    Clin Rheumatol; 2016 Aug; 35(8):2045-2051. PubMed ID: 27094945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
    Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
    Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
    [No Abstract]   [Full Text] [Related]  

  • 9. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
    Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
    J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
    Wang C; Yu Q; Jiang X; Deng Y; Sun F; Li X; Tao Y; Lin P; Ma Y; Zhu Y; Li C; Cao Y
    J Clin Pharmacol; 2023 Feb; 63(2):239-249. PubMed ID: 36131360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of SHR4640, a Selective Urate Transporter 1 Inhibitor, in Healthy Chinese Male Volunteers.
    Liang B; Wang J; Bai N; Zhuo J; Wang R; Lin H; Cai Y
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):392-396. PubMed ID: 36317751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
    Hou Z; Ma A; Mao J; Song D; Zhao X
    Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.
    Lee HA; Yu KS; Park SI; Yoon S; Onohara M; Ahn Y; Lee H
    Rheumatology (Oxford); 2019 Nov; 58(11):1976-1984. PubMed ID: 31056705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
    Hosoya T; Fushimi M; Okui D; Sasaki T; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):80-91. PubMed ID: 31875931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.